Search
GPI-0100
go.drugbank.com/drugs/DB05929InvestigationalGPI-0100 is Avantogen’s lead adjuvanat-immunopotentiator, a key component of vaccines for boosting the immune response. The GPI-0100 adjuvant, which has been shown to significantly enhance the immune response with a variety of vaccines, ...
FK352B
go.drugbank.com/drugs/DB06484ExperimentalFK352B is a adenosine A1 antagonist that is developed for the treatment of dialysis-induced hypotension.
Amisulpride
go.drugbank.com/drugs/DB06288ApprovedInvestigationalIn the US, the intravenous formulation of amisulpride is used to treat and prevent postoperative nausea and vomiting in adults, either as monotherapy or in combination with another antiemetic agent of
Sulisobenzone
go.drugbank.com/drugs/DB11185ApprovedSulisobenzone is approved by the FDA in concentrations of up to 10% and in Canada, is approved by Health Canada at the same concentrations [F38].
Pentoxifylline
go.drugbank.com/drugs/DB00806ApprovedInvestigational[A226608] Pentoxifylline has been marketed in Europe since 1972; PTX extended-release tablets sold under the trade name TRENTAL by US Pharm Holdings were first approved by the FDA on Aug 30, 1984, but
Amphetamine
go.drugbank.com/drugs/DB00182ApprovedIllicitInvestigationalThis use derived into a large overproduction of amphetamine and all the surplus after the war finalized ended up in the black market, producing the initiation of the illicit abuse.[A18540]
Briakinumab
go.drugbank.com/drugs/DB05459InvestigationalAs of 2011 drug development for psoriasis has been discontinued in the U.S. and Europe.
Bavituximab
go.drugbank.com/drugs/DB05136InvestigationalBavituximab is a chimeric Anti-PS monoclonal antibody analog which is used to potentially treat cancers and viral infections.
AdimrSC-2f
go.drugbank.com/drugs/DB16436InvestigationalThe AdimrSC-2f (SARS-CoV-2) vaccine is developed through Adimmune Corporation, the only influenza vaccine manufacturer with both EU GMP and US FDA certification in Asia[L30553].
Elexacaftor
go.drugbank.com/drugs/DB15444ApprovedInvestigationalElexacaftor (previously VX-445) is a small molecule, next-generation corrector of the cystic fibrosis transmembrane conductance regulator (CFTR) protein. It received FDA approval in October 2019 in combination with tezacaftor and ivacaft...